Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation

Fox Chase Cancer Center43 enrolled

Overview

This research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation. Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about genetic mutations or changes that occur in deoxyribonucleic acid (DNA) and help doctors understand how patients respond to treatment.

PRIMARY OBJECTIVES: I. To evaluate the tumor-specific mutation(s) detected using the CancerCode™ mutation panel as a predictor of pathologic response to chemoradiation for patients with rectal adenocarcinoma undergoing chemoradiation. SECONDARY OBJECTIVES: I. To assess the feasibility of utilizing biopsy specimens from locally advanced rectal adenocarcinoma to perform CancerCode™ mutation panel genetic testing. II. To assess disease-free survival (DFS) and overall survival (OS) of patients treated on study. III. To collect pilot data regarding the clonal heterogeneity of rectal adenocarcinoma, and the relationship of this heterogeneity with treatment response. IV. To evaluate the treatment response utilizing multiple fludeoxyglucose F 18-positron emission tomography (FDG-PET) parameters including heterogeneity and textural features as an exploratory study. OUTLINE: Patients undergo collection of blood and tissue samples for analysis via sequencing. After completion of study, patients are followed up every 3 months for 3 years.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Mucinous Adenocarcinoma of the Rectum Recurrent Rectal Cancer Signet Ring Adenocarcinoma of the Rectum

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Locally advanced rectal adenocarcinoma: T3-4NanyM0 or TanyN1-2M0 * Radiologically measurable or clinically evaluable disease * Provide informed written consent * Willing to return to enrolling medical site for all study assessments Exclusion Criteria: * Chemotherapy within 5 years prior to registration; (hormonal therapy is allowable if the disease free interval is \>= 5 years) * Any prior pelvic radiation * Patients who are at high risk of complications from temporarily discontinuing anticoagulation for rectal cancer biopsies

Outcomes

Primary Outcomes

Proportion of the randomly chosen samples that are successfully sequenced

If \>= 90% of the specimens (at least 72 out of 80) are useable, the method will be considered feasible.

Time frame: Up to 3 years

Tumor response measured using the tumor regression grading system

Whether mutations in any gene on the CancerCode mutation panel are associated with tumor response will be assessed. In each sample, the presence or absence of mutations (0/1) for each gene on the panel will be evaluated. Each gene will be tested separately for its association with tumor response using a two-sample Mann-Whitney-Wilcoxon test with a type-I error of 0.05 for a two-sided test.

Time frame: Up to 3 years

Secondary Outcomes

Tumor heterogeneity in patients with partial response to radiation

Whether there are differences in the mutation profiles in the 4 tumor samples will be assessed, with differences being considered evidence of possible heterogeneity.

Time frame: Up to 3 years

Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes